SB939 is analyzed by STAT3 to inhibit breast cancer cell metastasis-related genes

Abstract Background:The histone deacetylase inhibitor (HDACi) Pracinostat (SB939) plays a vital role in inhibiting metastasis of triple-negative breast cancer by downregulating FN1 expression levels through the STAT3 signaling pathway.SB939 has low cytotoxicity and may become a new generation of targeted agents against breast cancer tumors. This study aimed to investigate the association value of STAT3 and FN1 as breast cancer (BRCA) biomarkers and integrated several cancer databases and electronic computer technology to evaluate the effect of SB939 on breast cancer metastasis.Methods:GESA，GEPIA, GENT2,UALCAN, GeneMANIA, STRING,LinkedOmics, and TIMER were utilized in this study.Result:The analysis showed that SB939 inhibited the enrichment of the STAT3 pathway and affected the expression of FN1. Among them, FN1 expression was significantly higher in breast cancer tissues than in normal tissues, and in addition, STAT3 was highly expressed in many tumors. Kaplan-Meier curves showed that increased expression of STAT3 and FN1 correlated with low survival in breast cancer patients with OS, RFS, and DSS, and FN1 had the highest correlation with MMP2. Furthermore, MMP2 shares a pathway with STAT3 to induce metastasis of breast cancer cells.Conclusions: SB939 may be used as a new class of small molecule compounds in the clinic for the treatment of breast cancer.